Combined micro CT and histopathology for evaluation of skeletal metastasis in live animals.

Autor:	Geffre CP; Department of Pathology, University of Arizona College of Medicine Tucson, AZ 85724, USA., Pond E; University of Arizona Cancer Center Tucson, AZ 85724, USA., Pond GD; Department of Medical Imaging, University of Arizona College of Medicine Tucson, AZ 85724, USA., Sroka IC; Department of Pharmacology, University of Arizona College of Medicine Tucson, AZ 85724, USA., Gard JM; University of Arizona Cancer Center Tucson, AZ 85724, USA., Skovan BA; University of Arizona Cancer Center Tucson, AZ 85724, USA., Meek WE; University of Arizona Cancer Center Tucson, AZ 85724, USA., Landowski TH; Department of Medicine, University of Arizona College of Medicine Tucson, AZ 85724, USA., Nagle RB; Department of Pathology, University of Arizona College of Medicine Tucson, AZ 85724, USA., Cress AE; University of Arizona Cancer Center Tucson, AZ 85724, USA ; Department of Cellular and Molecular Medicine, University of Arizona College of Medicine Tucson, AZ 85724, USA.
Jazyk:	angličtina
Zdroj:	American journal of translational research [Am J Transl Res] 2015 Feb 15; Vol. 7 (2), pp. 348-55. Date of Electronic Publication: 2015 Feb 15 (Print Publication: 2015).
Abstrakt:	Bone is a favored site for solid tumor metastasis, especially among patients with breast, lung or prostate carcinomas. Micro CT is a powerful and inexpensive tool that can be used to investigate tumor progression in xenograft models of human disease. Many previous studies have relied on terminal analysis of harvested bones to document metastatic tumor activity. The current protocol uses live animals and combines sequential micro CT evaluation of lesion development with matched histopathology at the end of the study. The approach allows for both rapid detection and evaluation of bone lesion progression in live animals. Bone resident tumors are established either by direct (intraosseous) or arterial (intracardiac) injection, and lesion development is evaluated for up to eight weeks. This protocol provides a clinically relevant method for investigating bone metastasis progression and the development of osteotropic therapeutic strategies for the treatment of bone metastases.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu